Mehabe score: 5 G Factor: 4 Piotski Score: 9 The stock has a rating . The mehabe team score is reflective of its fundamental and technical merits. A rating above 8 is considered good buy. The stock has a G-Factor of 4 and Piotski score of 9.
Description
AHCL has been manufacturing ayurvedic balm for pain management since 1893, and is currently managed by the third-generation of promoters. The company is more than 120 years old and is into OTC products in the segments of pain management, women’s hygiene, and packaged fruit juice drink. [1] Site:AMRUTANJAN Main Symbol:AMRUTANJAN
Stock trades at 845.0, below its 50dma 882.15. However it is trading above its 200dma 796.03. The stock remains weak in the short term due to near term bearish momentum. However overall bullish structure remains intact. Price action will further build up as it moves above its dma50, currently situated at 882.15.
The 52 week high is at 1025.55 and the 52week low is at 439.40
Price Chart
P/E Chart
Sales and Margin
Strengths
– has reduced debt.
– is almost debt free.
– is expected to give good quarter
– has delivered good profit growth of 23.42% CAGR over last 5 years
– has been maintaining a healthy dividend payout of 23.37%
Weakness
– Stock is trading at 10.33 times its book value
Competition
– The industry trades at a mean P/E of 31.8x. Hester Bios trades at the industry’s max P/E of 47.44x. AMRUTANJAN trades at a P/E of 39.1x
– Industry’s mean G-Factor is 2.4 while the mean Piotski score is 9.0. AMRUTANJAN has a G-Factor of 4 and Piotski scoreof 9.
– Average 1 month return for industry is -6.5%. The max 1- month return was given by Laurus Labs: a return of 5.17 %
Quarterly Results
Sales for period ended Dec 2021 is Rs 111.0 cr compared to Rs 100.0 cr for period ended Dec 2020, a rise of 11.0% .
vis-vis 26.0 for period ended Dec 2020 .
Operating Margins contracted -257.7 bps for period ended Dec 2021 vis-vis Dec 2020.
Company reported operating profit of Rs 26.0 cr for period ended Dec 2021 and operating profit margin at 23.4 % for same period.
The EPS for quarter ended Dec 2021 is Rs 7.04 compared to Rs 6.79 for previous quarter ended Sep 2021 and Rs 7.18 for Dec 2020.
Profit & Loss Statement
Profit&Loss Comments
Company reported sales of Rs 393.0 cr for period ended TTM vis-vis sales of Rs 333.0 cr for the period ended Mar 2021, a healthy growth of 15.3%. The 3 year sales cagr stood at 15.8%.
Operating margins shrank to 19.0% for period ended TTM vis-vis 22.0% for period ended Mar 2021, contraction of 300.0 bps.
Net Profit reported at Rs 63.0 cr for period ended TTM vis-vis sales of Rs 61.0 cr for the period ended Mar 2021, rising 3.2%.
Company recorded a healthy Net Profit CAGR of 36.1% over the last 3 years
Balance Sheet Statement
Cash Flow Statement
Cash Flow comments
CashFlow from operating activities was positive.
CashFlow from operating activities: Rs 90.0 cr for period ended Mar 2021 vis-vis Rs 18.0 cr for period ended Mar 2020
Sales Growth
Profit Growth Statement
Profit Growth Statement
Stock Price CAGR
Return of Equity
General Comments
– The company has improved its Return on Equity (RoE) metric. The RoE on Last Year basis was 33.0% compared to 23.0% over the last 3 Years. – The stock has given a return of 44% on a 1 Year basis vis-vis a return of 44% over the last 3 Years. – The compounded sales growth on a TTM bassis is 36% vis-vis a compounded sales growth of 15% over the last 3 Years. – The compounded profit growth on a TTM basis is 33% vis-vis a compounded profit growth of 48% over the last 3 Years.
Ratios
Shareholding Pattern
– FII shareholding has remained largely constant. The Dec 2021 fii holding stood at 1.83% vis-vis 1.53% for Sep 2021 – Public shareholding has remained largely constant. The Dec 2021 public holding stood at 41.9% vis-vis 41.41% for Sep 2021
Conclusion
– has reduced debt.
– is almost debt free.
– is expected to give good quarter
– has delivered good profit growth of 23.42% CAGR over last 5 years
– has been maintaining a healthy dividend payout of 23.37% – Stock is trading at 10.33 times its book value
